Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF SELONSERTIB IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH)

Intervention/treatment:
SELONSERTIB (GS-4997)
Medical condition:
NONALCOHOLIC STEATOHEPATITIS (NASH)
Protocol code:
GS-US-384-1944
Control number:
202917
Status:
Closed
Approved:
March 09, 2017
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT03053063
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 70 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Gilead Clinical Study Information Center
Organization
Gilead Sciences
Phone:
1-833-445-3230 (GILEAD-0)
Sponsor
GILEAD SCIENCES CANADA INC

Locations

Alberta

GI Research
Edmonton, Alberta, T5H 4B9
University of Alberta
Edmonton, Alberta, T6G 2R3
University of Calgary Liver Unit (Heritage Medical Research Clinic)
Calgary, Alberta, T2N 4Z6

British Columbia

Gordon and Leslie Diamond Health Care Centre, Vancouver General Hospital, UBC Division of Gastroenterology
Vancouver, British Columbia, V5Z 1M9
LAIR Centre
Vancouver, British Columbia, V5Z 1HZ
PerCuro Clinical Research Ltd.
Victoria, British Columbia, V8T 5G4

Manitoba

University of Manitoba, Health Sciences Centre, John Buhler Research Centre
Winnipeg, Manitoba, R3E 3P4

Nova Scotia

South Shore Medical Arts
Bridgewater, Nova Scotia, B4V 3N2

Ontario

London Health Sciences Centre - University Hospital
London, Ontario, N6A 5A5
McMaster University Medical Centre
Hamilton, Ontario, L8S 4L8
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, L8N 4A6
Toronto Center for Liver Diseases (TCLD), Toronto General Hospital
Toronto, Ontario, M5G 2C4
Toronto Liver Centre
Toronto, Ontario, M6H 3M1
William Osler Health System-Brampton Civic Hospital
Brampton, Ontario, L6R 3J7

Quebec

Chronic Viral Illness Service/Royal Victoria Hospital/McGill University Health Centre (MUHC)
Montreal, Quebec, H4A 3JI

Results

See the results from the trial NCT03053063. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?